FDA clears more saline imports to address shortage

Federal health regulators are allowing a U.S. medical supply company to import saline solution from its Spanish plant to address a national shortage of the hospital staple.

The Food and Drug Administration announcement is the latest effort to increase U.S. supplies of the salt solution, which is used to rehydrate hospital patients and assist in the delivery of drugs.

The agency said late Monday that it cleared Baxter Healthcare to import from its facility in Spain after FDA inspectors verified that it meets U.S. standards. Last month the FDA cleared another company, Fresenius Kabi, to import saline from its Norway plant.

The FDA began receiving reports of a supply problem from hospitals in December due to production delays, maintenance problems and other issues.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA takes action to ease neonatal drug shortage

May 29, 2013

(AP)—Federal health regulators will allow overseas imports of a critical intravenous drug formula used to nourish premature infants, amid a shortage that has impacted hospitals nationwide.

US halts drug imports from Ranbaxy plant in India

Jan 23, 2014

U.S. health regulators said Thursday they are barring imported drugs from an overseas factory operated by Ranbaxy Laboratories, India's largest drugmaker, due to quality control violations.

Nitroglycerin shortage has medical community worried

Mar 27, 2014

(HealthDay)—An ongoing shortage of the drug nitroglycerin is causing problems and concerns for doctors and hospitals in the United States. The drug is often the first therapy used by emergency room doctors ...

Recommended for you

Supercomputers link proteins to drug side effects

15 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

22 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments